Sort by
Refine Your Search
-
Listed
-
Employer
-
Field
-
Full time research position, initial two-year fixed term with possibility of extension Opportunity to lead a research program in small molecule drug discovery Located at the Chemistry Building (F11
-
of Medical Research. The laboratory specialises in single-cell RNA sequencing, spatial transcriptomics and computational pipelines applied to patient biospecimens to understand the complexity of intestinal
-
Full time research position, initial two-year fixed term with possibility of extension Opportunity to lead a research program in peptide drug discovery Located at the Chemistry Building (F11
-
. To be successful in this position, you’ll have: PhD (or equivalent) in computational and/or theoretical chemistry or will complete a PhD in this field within the next six months. Experience in
-
+ 17% superannuation About the opportunity The Northern Sydney (Arabanoo) Precinct is welcoming applications for a Postdoc Research Associate - Imaging to join their team. The Northern Clinical School is
-
associated with subsurface H2 and CO2 storage in complex geological settings. Key foci of the experimental research program that the PDRA will undertake include: identifying secure sites for subsurface H2 and
-
coreflood facilities, and a geomodelling laboratory. Two key themes have been identified for this research program: 1) improved assessment of risk to hydrogen recovery posed by carbonate-clastic interbeds and
-
is identified. For further information For a confidential discussion regarding this position, contact: Mira Rajcevic GeoEnergy Project Officer School of Physics, Chemistry & Earth Sciences Ph - 831
-
Professor Jose Polo, Lead of the Cancer Epigenetics Program at the South Australian Immunogenomics Cancer Institute (SAiGENCI) and the Inaugural Director of the Adelaide Centre for Epigenetics (ACE). Together
-
Doctoral Scientist position. This position will report to Professor Jose Polo, Lead of the Cancer Epigenetics Program at the South Australian Immunogenomics Cancer Institute (SAiGENCI) and the Inaugural